Amy Fraser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Amy Fraser has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Giusy Di Conza
Onctura SA, Geneva, Switzerland
41 shared publications - Lars van der Veen
Onctura SA, Geneva, Switzerland
41 shared publications - Pritom Shah
Cancer Research Horizons, Cambridge, United Kingdom
41 shared publications - Zoë Johnson
Novimmune S.A., Plan-les-Ouates, Switzerland
41 shared publications - Andrea Rinaldi
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
32 shared publications - Chiara Tarantelli
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
32 shared publications
Latest Publications
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S4 shows LPAR expression in PDAC cell lines and ATX-mediated pro-tumorigenic stimulation by 0082T conditioned media.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S4 shows LPAR expression in PDAC cell lines and ATX-mediated pro-tumorigenic stimulation by 0082T conditioned media.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S3 shows ATX antibody validation and ATX detection in cancer and CAF co-cultures.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S3 shows ATX antibody validation and ATX detection in cancer and CAF co-cultures.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S5 shows RNA-seq analysis of 0082T CAFs after treatment with ATX inhibitors.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S5 shows RNA-seq analysis of 0082T CAFs after treatment with ATX inhibitors.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S6 shows LLPs expression in PDAC cancer and CAFs cells.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S6 shows LLPs expression in PDAC cancer and CAFs cells.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S2 shows the validation of 0082T CAF phenotype.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S2 shows the validation of 0082T CAF phenotype.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Table S1 shows the list of Taqman assays used for qPCR experiments.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Table S1 shows the list of Taqman assays used for qPCR experiments.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S1 shows the validation of ESTIMATE stromal and immune gene signatures and mRNA expression in tumour-rich and TME-rich samples.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Supplementary Figure S1 shows the validation of ESTIMATE stromal and immune gene signatures and mRNA expression in tumour-rich and TME-rich samples.
- Open Access
- 21 November 2024
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (2) , 230-241
Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Autotaxin (ATX), encoded by ENPP2, is a clinical target in pancreatic ductal adenocarcinoma (PDAC). ATX catalyzes the production of lysophosphatidic acid (LPA), an important regulator within the tumor microenvironment (TME), yet the protumorigenic action of the ATX/LPA axis in PDAC remains unclear. In this study, by interrogating patient samples and cell line datasets, we show that the PDAC TME, rather than cancer cells, is responsible for the majority of ENPP2 expression and highlight a key role for cancer-associated fibroblast (CAF)-derived ATX in autocrine and paracrine protumorigenic signaling. Using the clinical-stage ATX inhibitor, IOA-289, we identified connective tissue growth factor (CTGF), also known as CCN2, as a downstream mediator of ATX signaling in the PDAC CAF-derived cell line, 0082T. Genetic ablation or pharmacologic inhibition of ATX in 0082T CAFs reduced CTGF secretion via modulation of LPA/LPA receptor signaling. Despite the loss of ATX function, extracellular levels of LPA were paradoxically increased, indicating a role for ATX beyond its enzymatic activity and suggesting a role for its LPA chaperone function in the LPA/LPA receptor signaling in CAFs. As CAFs are the main source for CTGF in the PDAC TME, these findings suggest a role for ATX in promoting a protumorigenic microenvironment via modulation of CAF secretion not only via its LPA-producing activity but also via its LPA chaperone function, providing a potential mechanism for the antitumor effects of ATX inhibition.
- 21 November 2024
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (2) , 230-241
Open AccessPancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Autotaxin (ATX), encoded by ENPP2, is a clinical target in pancreatic ductal adenocarcinoma (PDAC). ATX catalyzes the production of lysophosphatidic acid (LPA), an important regulator within the tumor microenvironment (TME), yet the protumorigenic action of the ATX/LPA axis in PDAC remains unclear. In this study, by interrogating patient samples and cell line datasets, we show that the PDAC TME, rather than cancer cells, is responsible for the majority of ENPP2 expression and highlight a key role for cancer-associated fibroblast (CAF)-derived ATX in autocrine and paracrine protumorigenic signaling. Using the clinical-stage ATX inhibitor, IOA-289, we identified connective tissue growth factor (CTGF), also known as CCN2, as a downstream mediator of ATX signaling in the PDAC CAF-derived cell line, 0082T. Genetic ablation or pharmacologic inhibition of ATX in 0082T CAFs reduced CTGF secretion via modulation of LPA/LPA receptor signaling. Despite the loss of ATX function, extracellular levels of LPA were paradoxically increased, indicating a role for ATX beyond its enzymatic activity and suggesting a role for its LPA chaperone function in the LPA/LPA receptor signaling in CAFs. As CAFs are the main source for CTGF in the PDAC TME, these findings suggest a role for ATX in promoting a protumorigenic microenvironment via modulation of CAF secretion not only via its LPA-producing activity but also via its LPA chaperone function, providing a potential mechanism for the antitumor effects of ATX inhibition.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Correlation analysis of PI3Kd levels and the response to IOA-244 and Idelalisib
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Correlation analysis of PI3Kd levels and the response to IOA-244 and Idelalisib